From our data no conclusions can be drawn on the diagnostic performance of [99mTc]Tc-PSMA-I&S-SPECT/CT in comparison to other imaging modalities that are routinely recommended in advanced prostate cancer (e.g., CT, bone scintigraphy, whole body MRI). This evidence concerns the gene FOLH1 and prostate carcinoma.